Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma.

ABSTRACT:

Background

Isocitrate dehydrogenase (IDH) mutations are present in 70% of World Health Organization grade II and III gliomas. IDH mutation induces accumulation of the oncometabolite 2-hydroxyglutarate. Therefore, therapies targeting reversal of epigenetic dysregulation in gliomas have been suggested. However, the utility of epigenetic treatments in gliomas remains unclear. Here, we present the first clinical systematic review of epigenetic therapies in treatment of IDH-mutant gliomas and highlight their safety and efficacy.

Methods

We conducted a systematic search of electronic databases from 2000 to January 2021 following PRISMA guidelines. Articles were screened to include clinical usage of epigenetic therapies in case reports, prospective case series, or clinical trials.

SUBMITTER: Govindarajan V 

PROVIDER: S-EPMC9177782 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature